ORIC Pharmaceuticals Statistics
Total Valuation
ORIC has a market cap or net worth of $616.76 million. The enterprise value is $354.34 million.
Important Dates
The last earnings date was Tuesday, November 12, 2024, after market close.
| Earnings Date | Nov 12, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
ORIC has 70.57 million shares outstanding. The number of shares has increased by 41.07% in one year.
| Current Share Class | 70.57M |
| Shares Outstanding | 70.57M |
| Shares Change (YoY) | +41.07% |
| Shares Change (QoQ) | +0.28% |
| Owned by Insiders (%) | 1.54% |
| Owned by Institutions (%) | 70.25% |
| Float | 42.74M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 2.25 |
| P/TBV Ratio | 2.25 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 13.15, with a Debt / Equity ratio of 0.04.
| Current Ratio | 13.15 |
| Quick Ratio | 12.82 |
| Debt / Equity | 0.04 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -45.98% and return on invested capital (ROIC) is -31.07%.
| Return on Equity (ROE) | -45.98% |
| Return on Assets (ROA) | -29.22% |
| Return on Capital (ROIC) | -31.07% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.20M |
| Employee Count | 100 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +27.78% in the last 52 weeks. The beta is 1.12, so ORIC's price volatility has been higher than the market average.
| Beta (5Y) | 1.12 |
| 52-Week Price Change | +27.78% |
| 50-Day Moving Average | 9.62 |
| 200-Day Moving Average | 10.10 |
| Relative Strength Index (RSI) | 41.64 |
| Average Volume (20 Days) | 493,516 |
Short Selling Information
The latest short interest is 11.65 million, so 16.51% of the outstanding shares have been sold short.
| Short Interest | 11.65M |
| Short Previous Month | 12.00M |
| Short % of Shares Out | 16.51% |
| Short % of Float | 27.26% |
| Short Ratio (days to cover) | 29.34 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -134.75M |
| Pretax Income | -101.76M |
| Net Income | -119.87M |
| EBITDA | -133.69M |
| EBIT | -134.75M |
| Earnings Per Share (EPS) | -$1.80 |
Full Income StatementBalance Sheet
The company has $272.37 million in cash and $9.95 million in debt, giving a net cash position of $262.42 million or $3.72 per share.
| Cash & Cash Equivalents | 272.37M |
| Total Debt | 9.95M |
| Net Cash | 262.42M |
| Net Cash Per Share | $3.72 |
| Equity (Book Value) | 273.99M |
| Book Value Per Share | 3.88 |
| Working Capital | 258.18M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$108.88 million and capital expenditures -$1.03 million, giving a free cash flow of -$109.90 million.
| Operating Cash Flow | -108.88M |
| Capital Expenditures | -1.03M |
| Free Cash Flow | -109.90M |
| FCF Per Share | -$1.56 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |